COO vs HALO: fair value comparison
The Cooper Companies, Inc. and Halozyme Therapeutics, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HALO currently sits closer to the top of our discount ranking.
| COO | HALO | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $71.17 | $82.27 |
| 12-month range | $60.19–$83.92 | $63.96–$82.27 |
| Sector rank | #16 of 113 Healthcare | #14 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | A | A |
| Leverage | Low | High |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: COO fair value analysis · HALO fair value analysis